Nipocalimab Clinical Trials
8 recruitingDrug
Phase 38Phase 22
Showing 1–8 of 8 trials
Recruiting
Phase 3
A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
Hemolytic Disease of the Fetus and Newborn
Janssen Research & Development, LLC120 enrolled60 locationsNCT05912517
Recruiting
Phase 3
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
Lupus Erythematosus, Systemic
Janssen Research & Development, LLC600 enrolled27 locationsNCT07438496
Recruiting
Phase 3
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
Myasthenia Gravis
Janssen Research & Development, LLC115 enrolled8 locationsNCT07217587
Recruiting
Phase 2Phase 3
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Janssen Research & Development, LLC201 enrolled108 locationsNCT05327114
Recruiting
Phase 3
A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Thrombocytopenia, Neonatal Alloimmune
Janssen Research & Development, LLC39 enrolled21 locationsNCT06449651
Recruiting
Phase 3
A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Thrombocytopenia, Neonatal Alloimmune
Janssen Research & Development, LLC50 enrolled24 locationsNCT06533098
Recruiting
Phase 2Phase 3
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
Myasthenia Gravis
Janssen Research & Development, LLC12 enrolled19 locationsNCT05265273
Recruiting
Phase 3
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Myasthenia Gravis
Janssen Research & Development, LLC199 enrolled112 locationsNCT04951622